About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Cellectis S.A. v. Precision Biosciences Inc.
1:12-cv-00204; filed February 21, 2012 in the District Court of Delaware

Declaratory judgment of invalidity and non-infringement of U.S. Patent Nos. 8,119,361 ("Methods of Cleaving DNA with Rationally-Designed Meganucleases," issued February 21, 2012) and 8,119,381 ("Rationally Designed Meganucleases with Altered Sequence Specificity and DNA-Binding Affinity," issued February 21, 2012).  View the complaint here.

Precision BioSciences, Inc. v. Cellectis SA et al.
5:12-cv-00076; filed February 20, 2012 in the Eastern District of North Carolina

• Plaintiff:  Precision BioSciences, Inc.
• Defendants:  Cellectis SA; Cellectis bioresearch; Cellectis bioresearch Inc.

Infringement of U.S. Patent No. 8,119,361 ("Methods of Cleaving DNA with Rationally-Designed Meganucleases," issued February 21, 2012) based on Cellectis' manufacture, use, and sale of certain products, including meganucleases targeting the HIV1 genome.  View the complaint here.

Please see full update below for more information.